Medtronic has announced the worldwide launch of its Reveal LINQ insertable cardiac monitor (ICM) system, the smallest implantable cardiac monitoring device available for patients.
Medtronic has received CE Mark and the US Food and Drug Administration (FDA) 510(k) approvals for the Reveal LINQ ICM system.
According to the company, the device is approximately one-third the size of a AAA battery and is 80% smaller than other ICMs.
The company has designed the Reveal LINQ ICM system for patients who experience symptoms such as dizziness, palpitation, syncope (fainting) and chest pain that may suggest a cardiac arrhythmia, and for patients at increased risk for cardiac arrhythmias.
Reveal LINQ ICM system helps physicians to continuously and wirelessly monitor a patient’s heart for up to three years, with 20% more data memory than its larger predecessor, Reveal XT ICM system.
The miniaturised monitoring device features Carelink network system and MyCareLink patient monitor.
Carelink Network provides remote monitoring, allowing physicians to request notifications for alerting them if their patients have had cardiac events.
MyCareLink patient monitor is a simplified remote monitoring system with global cellular technology, which transmits patients’ cardiac device diagnostic data to their clinicians from nearly any location in the world.
The Reveal LINQ ICM is placed just beneath the skin through a small incision of less than 1cm in the upper left side of the chest using a minimally invasive insertion procedure. It is MR-Conditional, allowing patients to undergo magnetic resonance imaging if needed.
Medtronic senior vice-president and cardiac rhythm disease management president Pat Mackin said: "This is game-changing technology for patients who need cardiac monitoring, and we look forward to providing them with the most technologically advanced and minimally invasive approach possible."
Image: Medtronic Reveal XT insertable cardiac monitor. Photo: courtesy of Medtronic, Inc.